Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group SEC filings document financial results, governance actions and material events for a global health company operating through Cigna Healthcare, Evernorth Health Services and related subsidiaries. Form 8-K reports cover results of operations and financial condition, Regulation FD outlook disclosures, board and committee changes, leadership succession matters and shareholder meeting results.
Proxy materials describe director elections, executive compensation, shareholder voting items, board composition and governance practices. The filing record also includes exhibits for earnings releases and Inline XBRL cover data, tying formal disclosures to the company’s pharmacy benefit services, specialty and care services, health benefits operations, compliance oversight and public-company capital structure.
McClellan Mark B. reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Mark B. McClellan received a grant of 782 shares of common stock. The award was recorded at a price of $0.0000 per share, reflecting stock-based compensation rather than a market purchase. Following this grant, he directly holds 6,891 Cigna common shares.
Hathi Neesha reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Neesha Hathi received a grant of 782 shares of common stock as compensation. The shares were awarded at a stated price of $0.0000 per share, indicating a non-cash grant rather than an open-market purchase. Following this award, Hathi directly holds 4,151 Cigna Group shares.
ZARCONE DONNA F reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Donna F. Zarcone received an award of 782 shares of common stock on April 22, 2026. The grant was compensation-related, with no purchase price per share reported. Following this award, her directly owned holdings increased to 27,517 shares of Cigna common stock.
Her overall economic interest also includes cash-settled hypothetical shares tied to Cigna’s stock value, which are not shown in the share table because they are paid in cash rather than stock upon separation from service.
MAZZARELLA KATHLEEN M reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Kathleen M. Mazzarella received an equity grant of 782 shares of Cigna common stock. The award was recorded at a price of $0.00 per share, indicating it was a compensation-related grant rather than a market purchase. After this grant, she directly holds 6,891 Cigna shares.
Kurian George reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director George Kurian received an award of 782 shares of common stock on April 22, 2026. The shares were granted at $0.00 per share, increasing his directly held position to 4,560 shares of Cigna Group common stock.
A footnote explains that his economic interest also includes hypothetical shares whose value is tied to Cigna Group stock but settled in cash upon separation from service, so these cash-settled units are not included in the reported share totals.
Ross Kimberly A. reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Kimberly A. Ross received a stock award of 782 shares of Common Stock on April 22, 2026. The shares were granted at no stated purchase price, reflecting compensation rather than a market purchase.
After this award, Ross directly owns 5,294 shares of Cigna Group Common Stock.
Cigna Group director Michael J. Hennigan received a grant of 782 shares of Common Stock on April 22, 2026. The shares were acquired as a compensation-related grant or award at a stated price of $0.0000 per share. Following this transaction, he directly holds 1,350 shares of Cigna Group common stock.
Cigna Group director Philip Ozuah received a stock award that increased his direct ownership. On April 22, 2026, he acquired 782 shares of Cigna common stock through a grant/award acquisition at a stated price of $0.00 per share. After this award, his directly held position rose to 2,583 common shares. This appears to be a routine equity compensation grant rather than an open-market purchase or sale.
WISEMAN ERIC C reported acquisition or exercise transactions in this Form 4 filing.
Cigna Group director Eric C. Wiseman received an equity award of 782 shares of common stock, recorded at a price of $0.00 per share as a compensation grant. Following this award, he directly holds 23,940 common shares. The filing notes that his economic interest also includes cash-settled hypothetical shares tied to Cigna’s stock value, which are not counted in the reported share totals.
The Cigna Group EVP and General Counsel Andrea L. Nelson filed an initial ownership report showing existing stock and option holdings in Cigna Group common shares. This Form 3 does not report new buying or selling activity; it lists current positions.
Nelson holds 3,840 shares of common stock directly, plus 72.0769 shares indirectly through The Cigna Group’s 401(k) Plan. She also holds several employee stock options to buy common stock, with exercise prices ranging from $227.0200 to $336.4750 per share and expiration dates from 2032 to 2036. The options cover 453, 1,263, 1,090, 2,032, and 1,829 underlying shares, and each grant vests in three equal annual installments beginning on the dates specified in the footnotes.